Related Experiment Video

Updated: Jul 11, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

Total complement inhibition: an effective strategy to limit ischemic injury during coronary revascularization on

H L Lazar1, Y Bao, J Gaudiani

  • 1Department of Cardiothoracic Surgery, Boston University School of Medicine and Boston Medical Center, Boston, Mass 02118, USA.

Circulation
|September 29, 1999
PubMed

Insights

Combining soluble human complement receptor type 1 (sCR1) with heparin-bonded cardiopulmonary bypass (HB-CPB) significantly reduces myocardial damage during revascularization. This approach optimizes recovery by limiting ischemia-reperfusion injury.

Area of Science:

  • Cardiovascular Research
  • Immunology
  • Regenerative Medicine

Background:

  • Complement activation during myocardial revascularization exacerbates cardiac dysfunction.
  • Soluble human complement receptor type 1 (sCR1) and heparin-bonded cardiopulmonary bypass (HB-CPB) circuits inhibit complement.
  • The study investigated the combined effect of sCR1 and HB-CPB on myocardial damage.

Purpose of the Study:

  • To determine if combined sCR1 and HB-CPB limits myocardial damage during revascularization.
  • To evaluate the efficacy of total complement inhibition in reducing ischemia-reperfusion injury.

Main Methods:

  • A porcine model of myocardial ischemia-reperfusion was used (n=40).
  • Coronary arteries were occluded, followed by cardioplegic arrest and reperfusion.
  • Experimental groups included unmodified, sCR1 only, HB-CPB only, and combined sCR1 + HB-CPB.

Main Results:

  • The combined sCR1 + HB-CPB group showed significantly reduced myocardial acidosis (DeltapH -0.13).
  • Improved wall motion scores (3.59) and reduced lung water accumulation (1.24%) were observed in the combined group.
  • Combined therapy resulted in the smallest infarct size (20% of area at risk), significantly lower than other groups.

Conclusions:

  • Total complement inhibition using sCR1 and HB-CPB circuits optimizes myocardial recovery post-revascularization.
  • This combination therapy effectively mitigates ischemia-reperfusion injury.
Abstract

More Related Videos

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft05:25

Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft

Published on: September 15, 2023

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...